LaNova Medicines Announces IND Approval of LM-305 by US FDA

SHANGHAI, July 29, 2022 – LaNova Medicines announced that its GPRC5D-targeting antibody conjugate drug (ADC) LM-305 has received the approval of the US Food and Drug Administration (FDA) for investigation new drugs (IND). This study is an open-label, multi-center phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LM-305 in patients with multiple myeloma.

About GPRC5D

GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a member of the G protein-coupled receptors (GPCRs) family. As a novel GPCR drug target, GPRC5D is an orphan receptor for which no endogenous ligand has been found so far. GPRC5D is mainly expressed in malignant bone marrow plasma cells and hair follicles, but little or no expression in normal tissues. Studies have shown that GPRC5D is specifically highly expressed in multiple myeloma (MM) cells, and the expression level is relatively independent of BCMA, another target for multiple myeloma. Therefore, GPRC5D is expected to become the next treatment target for relapsed and refractory multiple myeloma (RRMM). As the first GPRC5D-directed ADC to enter the clinical development stage, LM-305 has the potential to become a first-in-class molecule.